Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Enlivex Therapeutics Ltd. for the month of March 2025. The filing serves to furnish the company's audited consolidated financial statements for the years ended December 31, 2024, and 2023, as well as the three-year period ended December 31, 2024.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the audited consolidated financial statements furnished as Exhibit 99.1 and incorporated by reference into the company's registration statements.
Material Changes
The filing text does not explicitly detail material changes versus prior periods. It references the inclusion of financial statements for the three-year period ended December 31, 2024, which would contain comparative data, but the specific changes are not summarized in this cover document.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document is a procedural filing to deliver audited financial statements to the SEC.
Investor Verification Checklist
- Review Exhibit 99.1 for the actual audited financial statements and numerical data for 2023 and 2024.
- Verify the incorporation of these statements into registration statements on Forms S-8, F-3, and F-3MEF (File Nos. 333-256799, 333-232413, 333-232009, 333-252926, and 333-264561).
- Confirm the audit opinion provided by Yarel + Partners (Exhibit 99.2).
- Check for any subsequent events or updates in the full text of the financial statements not summarized in this Form 6-K cover.